Ki-67 and CEA expression as prognostic markers in Dukes' C colorectal cancer

被引:43
作者
Ishida, H
Miwa, H
Tatsuta, M
Masutani, S
Imamura, H
Shimizu, J
Ezumi, K
Kato, H
Kawasaki, T
Furukawa, H
Kawakami, H
机构
[1] Sakai Municipal Hosp, Dept Surg, Sakai, Osaka 5900064, Japan
[2] Sakai Municipal Hosp, Dept Pathol, Sakai, Osaka 5900064, Japan
关键词
Dukes' C colorectal cancer; prognostic marker; Ki-67; antigen; CEA;
D O I
10.1016/j.canlet.2003.10.032
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study investigated the relationship between clinicopathological or immunohistochemical factors and postoperative prognosis for Dukes' C colorectal cancer. Short-term survivors died from cancer within 2 years of surgery, whereas long-term survivors were disease-free for over 10 years. The groups differed in Ki-67 antigen and CEA expression in colon cancer, and CEA expression in rectal cancer that was limited to the metastatic lymph nodes. The immunohistochemical scores were higher in short-term survivors. Our data suggest that the characteristics of metastatic lymph nodes are important as a predictor of the aggressiveness of tumor behavior and that the expression of Ki-67 antigen or CEA there may be a useful indicators of patients' survival in Dukes' C colorectal cancer. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:109 / 115
页数:7
相关论文
共 20 条
[1]  
Agui T, 2002, ANTICANCER RES, V22, P1769
[2]   DNA Ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients.: Result of a 5-year prospective study [J].
Bazan, V ;
Migliavacca, M ;
Zanna, I ;
Tubiolo, C ;
Corsale, S ;
Calò, V ;
Amato, A ;
Cammareri, P ;
Latteri, F ;
Grassi, N ;
Fulfaro, F ;
Porcasi, R ;
Morello, V ;
Nuara, RB ;
Dardanoni, G ;
Salerno, S ;
Valerio, MR ;
Dusonchet, L ;
Gerbino, A ;
Gebbia, N ;
Tomasino, RM ;
Russo, A .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (12) :650-658
[3]  
ISHIDA H, 2002, NIPPON SHOKAKIGEKA G, V35, P369
[4]   Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas [J].
Jansson, A ;
Sun, XF .
APMIS, 1997, 105 (09) :730-734
[5]  
Kressner U, 1995, ANTICANCER RES, V15, P2755
[6]  
KUBOTA Y, 1992, CANCER-AM CANCER SOC, V70, P2602, DOI 10.1002/1097-0142(19921201)70:11<2602::AID-CNCR2820701106>3.0.CO
[7]  
2-W
[8]   Determination of proliferative activity in colorectal carcinoma using monoclonal antibody Ki67 [J].
Kyzer, S ;
Gordon, PH .
DISEASES OF THE COLON & RECTUM, 1997, 40 (03) :322-325
[9]   FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas [J].
Mann, B ;
Gratchev, A ;
Böhm, C ;
Hanski, ML ;
Foss, HD ;
Demel, G ;
Trojanek, B ;
Schmidt-Wolf, I ;
Stein, H ;
Riecken, EO ;
Buhr, HJ ;
Hanski, C .
BRITISH JOURNAL OF CANCER, 1999, 79 (7-8) :1262-1269
[10]  
MORENO CG, 1998, REV ESP ENFERM DIG, V90, P391